Intersect ENT, Inc. (NASDAQ:XENT) – Analysts at William Blair issued their Q3 2017 earnings estimates for Intersect ENT in a research report issued to clients and investors on Monday. William Blair analyst K. Krum expects that the medical equipment provider will earn ($0.21) per share for the quarter. William Blair also issued estimates for Intersect ENT’s Q4 2017 earnings at ($0.17) EPS, Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.12) EPS, Q3 2018 earnings at ($0.14) EPS and Q4 2018 earnings at ($0.06) EPS.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.11. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The business had revenue of $24.00 million for the quarter, compared to the consensus estimate of $22.62 million. During the same quarter in the prior year, the business posted ($0.21) EPS. The business’s revenue for the quarter was up 24.4% on a year-over-year basis. TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/14/analysts-set-expectations-for-intersect-ent-inc-s-q3-2017-earnings-xent.html.

A number of other analysts have also issued reports on the company. Canaccord Genuity lifted their target price on Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday. Bank of America Corporation lifted their target price on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 target price on shares of Intersect ENT in a research report on Tuesday, August 22nd. TheStreet raised Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. Finally, BidaskClub lowered Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Intersect ENT presently has a consensus rating of “Buy” and an average price target of $27.11.

Intersect ENT (NASDAQ:XENT) opened at 30.30 on Wednesday. The stock’s market cap is $884.43 million. Intersect ENT has a 12-month low of $7.65 and a 12-month high of $33.25. The stock has a 50 day moving average price of $30.17 and a 200-day moving average price of $23.87.

In related news, CFO Jeryl L. Hilleman sold 12,835 shares of the business’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $27.18, for a total value of $348,855.30. Following the completion of the sale, the chief financial officer now directly owns 27,835 shares of the company’s stock, valued at $756,555.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Richard E. Kaufman sold 12,500 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $28.25, for a total value of $353,125.00. Following the completion of the sale, the chief operating officer now directly owns 169,821 shares of the company’s stock, valued at $4,797,443.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 113,426 shares of company stock valued at $3,346,685. 13.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in XENT. FMR LLC increased its holdings in Intersect ENT by 247.7% in the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock valued at $41,447,000 after buying an additional 1,056,389 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Intersect ENT by 2,746.9% in the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock valued at $26,036,000 after buying an additional 898,785 shares during the last quarter. Paulson & CO. Inc. bought a new stake in Intersect ENT in the first quarter valued at about $10,978,000. Lord Abbett & CO. LLC bought a new stake in Intersect ENT in the second quarter valued at about $9,384,000. Finally, Marshall Wace LLP bought a new stake in Intersect ENT in the first quarter valued at about $5,129,000. 83.12% of the stock is owned by hedge funds and other institutional investors.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.